Beth Snyder Bulik

Mod­er­na in­tro­duces sci­en­tist so­cial se­ries: Mod­er­na is invit­ing LinkedIn and In­sta­gram scrollers to take a break with its sci­en­tists in a Cof­fee Break Sci­ence se­ries

Re­al Chem­istry plans to har­ness the “Wild West” of GLP-1 so­cial me­dia and reams of com­pet­i­tive da­ta in the drug cat­e­go­ry with a new plat­form

Pa­tient ad­vo­ca­cy groups’ per­cep­tion of phar­ma com­pa­nies fell for the first time since be­gin­ning a steady rise five years ago, a sign that the in­dus­try

The lead­ing TV ad-spend­ing drug brand is get­ting a cam­paign re­fresh for one of its in­di­ca­tions. Sanofi and Re­gen­eron re­newed the ef­fort for Dupix­ent in

Ipsen’s new spon­sored Tik­Tok fea­tures the pop­u­lar “Of course” trend and two so­cial in­flu­encers, but with a rare dis­ease twist. The short video shows two

Gilead Sci­ences notched “fine” sales for the first quar­ter but the bio­phar­ma promised more to come. Gilead re­port­ed sales of $6.6 bil­lion, a 5% in­crease year-over-year,

Fol­low­ing a re­cent move to ask Con­gress to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars, the FDA on Wednes­day pro­posed up­dat­ed guid­ance on the la­bel­ing and

Sage Ther­a­peu­tics is dou­bling down on the “block­buster po­ten­tial” of its post­par­tum de­pres­sion drug Zurzu­vae, ex­pand­ing pro­fes­sion­al pro­mo­tions and tak­ing steps to­ward a di­rect-to-con­sumer launch

Neu­ro­crine Bio­sciences’ new­ly-de­buted cam­paign ac­knowl­edges the frus­tra­tion that con­gen­i­tal adren­al hy­per­pla­sia (CAH) pa­tients, fam­i­lies and en­docri­nol­o­gists of­ten feel. The “What the C@H?!” theme is a

Stephanie De­Vi­teri is tak­ing over as In­izio Evoke Comms’ pres­i­dent for North Amer­i­ca, re­turn­ing to the agency where she spent 20 years af­ter a two-year